← Back to Search

Local Anesthetic

ESPB Solutions for Breast Cancer

Phase 2
Waitlist Available
Research Sponsored by Tufts Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights

Summary

This trial will compare pain scores of two different methods of pain management for subjects undergoing bilateral surgical intervention for breast cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pain Score at 48 hours
Secondary study objectives
Pain Scores at 6, 12, 18, 24, 30, 38, 42, and 72 hours

Trial Design

2Treatment groups
Active Control
Group I: ControlActive Control1 Intervention
Control arm will receive standard of care solution for the ESPB block
Group II: Liposomal BupivicaineActive Control1 Intervention
Liposomal Bupivicaine arm will receive Liposomal Bupivicaine for the ESPB block

Find a Location

Who is running the clinical trial?

Tufts Medical CenterLead Sponsor
261 Previous Clinical Trials
264,120 Total Patients Enrolled
4 Trials studying Breast Cancer
1,776 Patients Enrolled for Breast Cancer

Media Library

Liposomal bupivacaine (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT04603911 — Phase 2
Breast Cancer Research Study Groups: Control, Liposomal Bupivicaine
Breast Cancer Clinical Trial 2023: Liposomal bupivacaine Highlights & Side Effects. Trial Name: NCT04603911 — Phase 2
Liposomal bupivacaine (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04603911 — Phase 2
~16 spots leftby Sep 2025